PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	AZD 1480	124-131	interleukin 17A	Homo sapiens	26-32
34685476-2	2021	In the present study, we identified increased isoprenaline-induced aa-nat expression and nocturnal AANAT activity in the pineal glands in response to the silencing of the signal transducer and activator of transcription 3 (STAT3) with siRNA or STAT3 inhibitors WP1066 and AZD1480.	AZD 1480	272-279	aralkylamine N-acetyltransferase	Rattus norvegicus	99-104
34685476-2	2021	In the present study, we identified increased isoprenaline-induced aa-nat expression and nocturnal AANAT activity in the pineal glands in response to the silencing of the signal transducer and activator of transcription 3 (STAT3) with siRNA or STAT3 inhibitors WP1066 and AZD1480.	AZD 1480	272-279	signal transducer and activator of transcription 3	Rattus norvegicus	244-249
35207737-8	2022	Since Janus kinases2 (JAK2) was considered as one of the down-stream kinases under IL4Ralpha and IL13Ralpha1 complex, the same kinds of experiments were performed in SNU308 cells treated with AZD1480, Janus-associated kinases2 (JAK2) inhibitor, to demonstrate the cytotoxic effect of AZD1480 in SNU308 cells.	AZD 1480	192-199	Janus kinase 2	Homo sapiens	22-26
35207737-8	2022	Since Janus kinases2 (JAK2) was considered as one of the down-stream kinases under IL4Ralpha and IL13Ralpha1 complex, the same kinds of experiments were performed in SNU308 cells treated with AZD1480, Janus-associated kinases2 (JAK2) inhibitor, to demonstrate the cytotoxic effect of AZD1480 in SNU308 cells.	AZD 1480	284-291	Janus kinase 2	Homo sapiens	22-26
35207737-12	2022	Then, we found that knockdown of IL4Ralpha or IL13Ralpha1 decreased viability and induced apoptosis in SNU308 cells via activation of FOXO3 and similarly, AZD1480 decreased viability and induced apoptosis in SNU308 cells with dose dependent manner.	AZD 1480	155-162	interleukin 4 receptor	Homo sapiens	33-42
35207737-12	2022	Then, we found that knockdown of IL4Ralpha or IL13Ralpha1 decreased viability and induced apoptosis in SNU308 cells via activation of FOXO3 and similarly, AZD1480 decreased viability and induced apoptosis in SNU308 cells with dose dependent manner.	AZD 1480	155-162	interleukin 13 receptor subunit alpha 1	Homo sapiens	46-57
34904774-4	2022	The JAK2 inhibitor AZD-1480 was introduced to explore the specific mechanism by which IVM regulates glycolysis and autophagy.	AZD 1480	19-27	Janus kinase 2	Rattus norvegicus	4-8
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	AZD 1480	124-131	signal transducer and activator of transcription 3	Homo sapiens	41-46
32783069-8	2021	RESULTS: Stimulation with IL-17A induced STAT3 phosphorylation, which was inhibited by the pretreatment with JAK2 inhibitor AZD1480 or JAK1/3 inhibitor tofacitinib.	AZD 1480	124-131	Janus kinase 2	Homo sapiens	109-113
33102814-9	2020	Furthermore, while JAK2 inhibition leads to decreased viability in SeAx cells (IC50 of 9.98 and 29.15 muM for AZD1480 and ruxolitinib respectively), both JAK1 and JAK3 do not.	AZD 1480	110-117	Janus kinase 2	Homo sapiens	19-23
30007232-15	2018	In contrast, AZD1480, a JAK2 inhibitor, abolished this SN-EPO effect.	AZD 1480	13-20	Janus kinase 2	Mus musculus	24-28
30604628-7	2019	In addition, inhibiting Janus activated kinase (JAK) 2 by either siRNA or a selective pharmacological inhibitor, AZD1480-but not a JAK1/JAK3 selective inhibitor, tofacitinib-also significantly reduced this IL-17A-induced fibrogenic response.	AZD 1480	113-120	interleukin 17A	Homo sapiens	206-212
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	interleukin 6	Homo sapiens	18-22
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	signal transducer and activator of transcription 3	Homo sapiens	27-32
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	Janus kinase 1	Homo sapiens	50-56
32768575-10	2020	Inhibition of the IL-6/JAK/STAT3 pathway with the JAK1/2 specific inhibitor, AZD1480, reversed the associated increase of IL-6.	AZD 1480	77-84	interleukin 6	Homo sapiens	122-126
32144852-7	2020	Furthermore, treatment of JAK2 clinical medicine AZD1480 to ESCC cells showed similar tendency with Lico B.	AZD 1480	49-56	Janus kinase 2	Homo sapiens	26-30
32005799-5	2020	Interruption of IL-6/JAK/STAT3 pathway by a JAK inhibitor AZD1480 reverses the pro-metastatic effect of sevoflurane and the associated increase of both activated STAT3 and infiltrated CD11b+ cells in 4T1 model.	AZD 1480	58-65	interleukin 6	Homo sapiens	16-20
32005799-5	2020	Interruption of IL-6/JAK/STAT3 pathway by a JAK inhibitor AZD1480 reverses the pro-metastatic effect of sevoflurane and the associated increase of both activated STAT3 and infiltrated CD11b+ cells in 4T1 model.	AZD 1480	58-65	signal transducer and activator of transcription 3	Homo sapiens	25-30
32005799-5	2020	Interruption of IL-6/JAK/STAT3 pathway by a JAK inhibitor AZD1480 reverses the pro-metastatic effect of sevoflurane and the associated increase of both activated STAT3 and infiltrated CD11b+ cells in 4T1 model.	AZD 1480	58-65	signal transducer and activator of transcription 3	Homo sapiens	162-167
32005799-5	2020	Interruption of IL-6/JAK/STAT3 pathway by a JAK inhibitor AZD1480 reverses the pro-metastatic effect of sevoflurane and the associated increase of both activated STAT3 and infiltrated CD11b+ cells in 4T1 model.	AZD 1480	58-65	integrin subunit alpha M	Homo sapiens	184-189
31467427-3	2019	In this study, using lipopolysaccharide (LPS) inhalation plus mechanical ventilation as VILI mouse model, we found that the administration of JAK2 inhibitor AZD1480 markedly attenuated lung destruction, diminished protein leakage, and inhibited cytokine release.	AZD 1480	157-164	Janus kinase 2	Mus musculus	142-146
31467427-4	2019	In addition, when mouse macrophage-like RAW 264.7 cells were exposed to LPS and cyclic stretch (CS), AZD1480 prevented cell autophagy, reduced apoptosis, and suppressed lactate dehydrogenase release by downregulating JAK2/STAT1 phosphorylation levels and inducing HMGB1 translocation from the nucleus to the cytoplasm.	AZD 1480	101-108	Janus kinase 2	Mus musculus	217-221
31467427-4	2019	In addition, when mouse macrophage-like RAW 264.7 cells were exposed to LPS and cyclic stretch (CS), AZD1480 prevented cell autophagy, reduced apoptosis, and suppressed lactate dehydrogenase release by downregulating JAK2/STAT1 phosphorylation levels and inducing HMGB1 translocation from the nucleus to the cytoplasm.	AZD 1480	101-108	signal transducer and activator of transcription 1	Mus musculus	222-227
31467427-4	2019	In addition, when mouse macrophage-like RAW 264.7 cells were exposed to LPS and cyclic stretch (CS), AZD1480 prevented cell autophagy, reduced apoptosis, and suppressed lactate dehydrogenase release by downregulating JAK2/STAT1 phosphorylation levels and inducing HMGB1 translocation from the nucleus to the cytoplasm.	AZD 1480	101-108	high mobility group box 1	Mus musculus	264-269
30015925-8	2018	The use of the JAK2 inhibitor, AZD-1480, attenuated the suppressive effects of LKB1 overexpression on the growth, metastasis and self-renewal ability of the GBC cells, which further demonstrated that JAK/STAT3 was involved in the LKB1-induced suppression of GBC cell growth, metastasis and self-renewal ability.	AZD 1480	31-39	Janus kinase 2	Homo sapiens	15-19
30015925-8	2018	The use of the JAK2 inhibitor, AZD-1480, attenuated the suppressive effects of LKB1 overexpression on the growth, metastasis and self-renewal ability of the GBC cells, which further demonstrated that JAK/STAT3 was involved in the LKB1-induced suppression of GBC cell growth, metastasis and self-renewal ability.	AZD 1480	31-39	serine/threonine kinase 11	Homo sapiens	79-83
30015925-8	2018	The use of the JAK2 inhibitor, AZD-1480, attenuated the suppressive effects of LKB1 overexpression on the growth, metastasis and self-renewal ability of the GBC cells, which further demonstrated that JAK/STAT3 was involved in the LKB1-induced suppression of GBC cell growth, metastasis and self-renewal ability.	AZD 1480	31-39	signal transducer and activator of transcription 3	Homo sapiens	204-209
30015925-8	2018	The use of the JAK2 inhibitor, AZD-1480, attenuated the suppressive effects of LKB1 overexpression on the growth, metastasis and self-renewal ability of the GBC cells, which further demonstrated that JAK/STAT3 was involved in the LKB1-induced suppression of GBC cell growth, metastasis and self-renewal ability.	AZD 1480	31-39	serine/threonine kinase 11	Homo sapiens	230-234
30007232-15	2018	In contrast, AZD1480, a JAK2 inhibitor, abolished this SN-EPO effect.	AZD 1480	13-20	erythropoietin	Mus musculus	55-61
30038287-8	2018	Further work demonstrated that the combination of PD98059 with AZD1480 could reverse the effects of PEAK1-induced EMT, cell migration and invasion.	AZD 1480	63-70	pseudopodium enriched atypical kinase 1	Homo sapiens	100-105
29722127-4	2018	Functional analysis was conducted by siRNA-mediated CD90, Gli1 and Gli3 gene knockdown, SHH treatment and application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody in CD90+ liver cancer stem cells, followed by cell proliferation, migration, sphere formation and tumorigenicity assays.	AZD 1480	140-147	Janus kinase 2	Homo sapiens	125-129
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	Janus kinase 2	Homo sapiens	19-23
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	Thy-1 cell surface antigen	Homo sapiens	83-87
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	sonic hedgehog signaling molecule	Homo sapiens	92-95
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	GLI family zinc finger 1	Homo sapiens	96-99
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	interleukin 6	Homo sapiens	164-167
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	Janus kinase 2	Homo sapiens	168-172
29722127-8	2018	Application of the JAK2 inhibitor AZD1480 and IL6 neutralizing antibody showed the CD90 and SHH/Gli-regulated liver cancer stem cell functions were mediated by the IL6/JAK2/STAT3 pathway.	AZD 1480	34-41	signal transducer and activator of transcription 3	Homo sapiens	173-178
29102603-7	2017	Moreover, the expression levels of p-JAK2 and p-STAT3 were significantly increased in the cortex after SAH induction and were further increased by EPO treatment; in addition, the p-JAK2 inhibitor AZD1480 impaired the protective effect of EPO against SAH-induced EBI in vivo.	AZD 1480	196-203	Janus kinase 2	Homo sapiens	37-41
29345196-10	2018	Hyperactivation of pSTAT3 and inflammation were rescued by AZD1480, a JAK1/2 inhibitor.	AZD 1480	59-66	Janus kinase 1	Mus musculus	70-76
29102603-7	2017	Moreover, the expression levels of p-JAK2 and p-STAT3 were significantly increased in the cortex after SAH induction and were further increased by EPO treatment; in addition, the p-JAK2 inhibitor AZD1480 impaired the protective effect of EPO against SAH-induced EBI in vivo.	AZD 1480	196-203	erythropoietin	Homo sapiens	238-241
29102603-7	2017	Moreover, the expression levels of p-JAK2 and p-STAT3 were significantly increased in the cortex after SAH induction and were further increased by EPO treatment; in addition, the p-JAK2 inhibitor AZD1480 impaired the protective effect of EPO against SAH-induced EBI in vivo.	AZD 1480	196-203	signal transducer and activator of transcription 3	Homo sapiens	48-53
29102603-7	2017	Moreover, the expression levels of p-JAK2 and p-STAT3 were significantly increased in the cortex after SAH induction and were further increased by EPO treatment; in addition, the p-JAK2 inhibitor AZD1480 impaired the protective effect of EPO against SAH-induced EBI in vivo.	AZD 1480	196-203	erythropoietin	Homo sapiens	147-150
29102603-7	2017	Moreover, the expression levels of p-JAK2 and p-STAT3 were significantly increased in the cortex after SAH induction and were further increased by EPO treatment; in addition, the p-JAK2 inhibitor AZD1480 impaired the protective effect of EPO against SAH-induced EBI in vivo.	AZD 1480	196-203	Janus kinase 2	Homo sapiens	181-185
29312610-0	2017	Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.	AZD 1480	84-91	ALK receptor tyrosine kinase	Homo sapiens	30-33
29312610-0	2017	Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.	AZD 1480	84-91	leukocyte receptor tyrosine kinase	Homo sapiens	35-38
29312610-0	2017	Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.	AZD 1480	84-91	ret proto-oncogene	Homo sapiens	46-49
29312610-3	2017	Here, we searched for novel targets of AZD1480, an inhibitor of JAK2 kinase that recently failed phase two cancer clinical trials due to a lack of activity.	AZD 1480	39-46	Janus kinase 2	Homo sapiens	64-68
29312610-5	2017	We demonstrate that AZD1480 inhibits ALK, LTK, FGFR1-3, RET and TRKA-C kinases and uncover a physical basis of this specificity.	AZD 1480	20-27	ALK receptor tyrosine kinase	Homo sapiens	37-40
29312610-5	2017	We demonstrate that AZD1480 inhibits ALK, LTK, FGFR1-3, RET and TRKA-C kinases and uncover a physical basis of this specificity.	AZD 1480	20-27	leukocyte receptor tyrosine kinase	Homo sapiens	42-45
29312610-5	2017	We demonstrate that AZD1480 inhibits ALK, LTK, FGFR1-3, RET and TRKA-C kinases and uncover a physical basis of this specificity.	AZD 1480	20-27	fibroblast growth factor receptor 1	Homo sapiens	47-54
29312610-5	2017	We demonstrate that AZD1480 inhibits ALK, LTK, FGFR1-3, RET and TRKA-C kinases and uncover a physical basis of this specificity.	AZD 1480	20-27	ret proto-oncogene	Homo sapiens	56-59
29228586-7	2017	Hypoxia-induced p-STAT3 increased the mRNA transcription of ICAM-1, which we could inhibit with the STAT3 inhibitor AZD1480.	AZD 1480	116-123	signal transducer and activator of transcription 3	Mus musculus	18-23
28960447-0	2017	JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.	AZD 1480	18-25	Janus kinase 1	Canis lupus familiaris	0-4
28960447-4	2017	AZD1480 and CYT387 are novel JAK1/2 inhibitors that have been used in clinical trials for treating various hematologic cancers in humans.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	29-35
28960447-6	2017	HYPOTHESIS/OBJECTIVES: We hypothesize that JAK1/2 inhibitors AZD1480 and CYT387 can effectively inhibit growth of canine DLBCL in vitro.	AZD 1480	61-68	Janus kinase 1	Canis lupus familiaris	43-47
29228586-7	2017	Hypoxia-induced p-STAT3 increased the mRNA transcription of ICAM-1, which we could inhibit with the STAT3 inhibitor AZD1480.	AZD 1480	116-123	signal transducer and activator of transcription 3	Mus musculus	100-105
29228586-7	2017	Hypoxia-induced p-STAT3 increased the mRNA transcription of ICAM-1, which we could inhibit with the STAT3 inhibitor AZD1480.	AZD 1480	116-123	intercellular adhesion molecule 1	Mus musculus	60-66
26510863-7	2015	The strongest effects were observed by suppressing JAK1/2 signaling with AZD1480.	AZD 1480	73-80	Janus kinase 1	Bos taurus	51-55
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	integrin subunit alpha M	Homo sapiens	22-27
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	Janus kinase 1	Homo sapiens	52-59
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	integrin subunit alpha M	Homo sapiens	300-305
28039266-8	2017	Transient blockade of CD11b+ cell expansion using a JAK 1/2 Inhibitor (AZD1480) impaired mobilization of these cells and was associated with a reduction in tumor volume, maintenance of a low-grade tumor phenotype, and prolongation in survival.Conclusions: We demonstrate that impaired recruitment of CD11b+ myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model.	AZD 1480	71-78	Janus kinase 1	Homo sapiens	328-334
27147665-6	2016	In vitro, alpha-SYN exposure activated the JAK/STAT pathway in microglia and macrophages, and treatment with AZD1480 inhibited alpha-SYN-induced major histocompatibility complex Class II and inflammatory gene expression in microglia and macrophages by reducing STAT1 and STAT3 activation.	AZD 1480	109-116	Janus kinase 1	Rattus norvegicus	43-46
27147665-6	2016	In vitro, alpha-SYN exposure activated the JAK/STAT pathway in microglia and macrophages, and treatment with AZD1480 inhibited alpha-SYN-induced major histocompatibility complex Class II and inflammatory gene expression in microglia and macrophages by reducing STAT1 and STAT3 activation.	AZD 1480	109-116	signal transducer and activator of transcription 1	Rattus norvegicus	261-266
27147665-6	2016	In vitro, alpha-SYN exposure activated the JAK/STAT pathway in microglia and macrophages, and treatment with AZD1480 inhibited alpha-SYN-induced major histocompatibility complex Class II and inflammatory gene expression in microglia and macrophages by reducing STAT1 and STAT3 activation.	AZD 1480	109-116	signal transducer and activator of transcription 3	Rattus norvegicus	271-276
27147665-8	2016	AZD1480 treatment inhibited alpha-SYN-induced neuroinflammation by suppressing microglial activation, macrophage and CD4(+) T-cell infiltration and production of proinflammatory cytokines/chemokines.	AZD 1480	0-7	Cd4 molecule	Rattus norvegicus	117-120
27147665-13	2016	Using an alpha-SYN overexpression PD model, we demonstrate a beneficial therapeutic effect of AZD1480, a specific inhibitor of JAK1/2, in suppressing neuroinflammation and neurodegeneration.	AZD 1480	94-101	Janus kinase 1	Rattus norvegicus	127-133
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	discoidin domain receptor tyrosine kinase 2	Homo sapiens	63-67
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	insulin like growth factor 1 receptor	Homo sapiens	69-74
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	fms related receptor tyrosine kinase 3	Homo sapiens	76-80
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	neurotrophic receptor tyrosine kinase 1	Homo sapiens	82-86
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	fms related receptor tyrosine kinase 4	Homo sapiens	88-92
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	94-97
26494904-8	2016	This was most extensive in SU5402 and AZD1480, which inhibited DDR2, IGF1R, FLT3, TRKA, FLT4, ABL and JAK3 with efficiencies similar to or greater than those for FGFR.	AZD 1480	38-45	Janus kinase 3	Homo sapiens	102-106
28292965-6	2017	The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytokines on mouse and human beta-cells by inhibiting MHC class I upregulation.	AZD 1480	24-31	Janus kinase 1	Mus musculus	4-8
28292965-6	2017	The JAK1/JAK2 inhibitor AZD1480 blocked the effect of cytokines on mouse and human beta-cells by inhibiting MHC class I upregulation.	AZD 1480	24-31	Janus kinase 2	Mus musculus	9-13
27976373-9	2017	AZD1480, an ATP-competitive JAK2 inhibitor, abrogated the observed TAM-mediated MM cell survival, and partially inhibited resistance to bortezomib.	AZD 1480	0-7	Janus kinase 2	Mus musculus	28-32
27976373-12	2017	As a result of TAM-induced activation of the STAT3 pathway, 5T33MM cells are sensitized to AZD1480 treatment.	AZD 1480	91-98	signal transducer and activator of transcription 3	Mus musculus	45-50
25704089-0	2015	The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells.	AZD 1480	19-26	Janus kinase 2	Homo sapiens	4-8
26419724-3	2015	Using in vitro drug screening, we identified 211 amino-acid substitutions conferring resistance to ruxolitinib (INCB018424) and cross-resistance to the JAK2 inhibitors AZD1480, CYT-387 and lestaurtinib.	AZD 1480	168-175	Janus kinase 2	Homo sapiens	152-156
25646015-8	2015	AZD1480 treatment inhibited STAT3 phosphorylation and DNA binding, and migration and adhesion of cultured ovarian carcinoma cells and ovarian tumor growth rate, volume, and ascites production in mice.	AZD 1480	0-7	signal transducer and activator of transcription 3	Mus musculus	28-33
25704089-1	2015	The JAK2 inhibitor AZD1480 has been reported to inhibit La protein expression.	AZD 1480	19-26	Janus kinase 2	Homo sapiens	4-8
25704089-6	2015	Furthermore, AZD1480 inhibited the expression of phosphorylated-(Tyr-705)-signal transducer and activator of transcription 3 (STAT3) and La in Huh7 cells.	AZD 1480	13-20	signal transducer and activator of transcription 3	Homo sapiens	74-124
25704089-6	2015	Furthermore, AZD1480 inhibited the expression of phosphorylated-(Tyr-705)-signal transducer and activator of transcription 3 (STAT3) and La in Huh7 cells.	AZD 1480	13-20	signal transducer and activator of transcription 3	Homo sapiens	126-131
25810010-2	2015	AZD1480, an orally active pharmacologic inhibitor of JAK1/JAK2, has been tested in several cancer models.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	53-57
25810010-2	2015	AZD1480, an orally active pharmacologic inhibitor of JAK1/JAK2, has been tested in several cancer models.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	58-62
25504635-2	2015	The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts.	AZD 1480	89-96	Janus kinase 1	Homo sapiens	72-76
25530567-0	2015	A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.	AZD 1480	64-71	Janus kinase 2	Homo sapiens	49-53
25216185-0	2014	AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	100-104
24953013-9	2014	The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation.	AZD 1480	53-60	Janus kinase 2	Homo sapiens	18-22
24953013-9	2014	The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation.	AZD 1480	53-60	Janus kinase 2	Homo sapiens	29-33
24953013-9	2014	The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation.	AZD 1480	53-60	aurora kinase A	Homo sapiens	96-101
24953013-9	2014	The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation.	AZD 1480	53-60	aurora kinase A	Homo sapiens	132-137
24953013-9	2014	The inhibition of JAK2 using JAK2-specific inhibitor AZD1480 or siRNA knockdown, in presence of AURKA overexpression, abrogated the AURKA-mediated STAT3 activation.	AZD 1480	53-60	signal transducer and activator of transcription 3	Homo sapiens	147-152
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	CD34 molecule	Homo sapiens	58-62
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	Janus kinase 1	Homo sapiens	81-89
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	CD34 molecule	Homo sapiens	141-145
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	CD34 molecule	Homo sapiens	141-145
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	Thy-1 cell surface antigen	Homo sapiens	157-161
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	CD34 molecule	Homo sapiens	141-145
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	Janus kinase 2	Homo sapiens	271-275
25193869-3	2014	The in vitro treatment of splenic and peripheral blood MF CD34(+) cells with the JAK1/2/3 inhibitor, AZD1480, reduced the absolute number of CD34(+), CD34(+)CD90(+), and CD34(+)CXCR4(+) cells as well as assayable hematopoietic progenitor cells (HPCs) irrespective of the JAK2 and calreticulin mutational status.	AZD 1480	101-108	calreticulin	Homo sapiens	280-292
25131802-0	2014	Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.	AZD 1480	41-48	Janus kinase 1	Homo sapiens	66-87
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	AZD 1480	12-19	Janus kinase 1	Homo sapiens	55-76
25131802-1	2014	BACKGROUND: AZD1480 is an ATP competitive inhibitor of Janus kinases 1 and 2 (JAK1, 2) that has been shown to inhibit the growth of solid tumor models.	AZD 1480	12-19	Janus kinase 1	Homo sapiens	78-82
25216185-0	2014	AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.	AZD 1480	0-7	signal transducer and activator of transcription 3	Homo sapiens	105-110
25216185-2	2014	To develop novel therapies for CRC, we have explored the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK/STAT3 pathway and its potential antitumor activity on the human CRC cell lines (HCT116, HT29 and SW480).	AZD 1480	106-113	interleukin 6	Homo sapiens	118-122
25216185-2	2014	To develop novel therapies for CRC, we have explored the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK/STAT3 pathway and its potential antitumor activity on the human CRC cell lines (HCT116, HT29 and SW480).	AZD 1480	106-113	signal transducer and activator of transcription 3	Homo sapiens	127-132
25216185-3	2014	The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells.	AZD 1480	25-32	interleukin 6	Homo sapiens	71-75
25216185-3	2014	The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells.	AZD 1480	25-32	Janus kinase 2	Homo sapiens	84-88
25216185-3	2014	The results showed that, AZD1480 effectively prevents constitutive and IL-6-induced JAK2 and STAT-3 phosphorylation and exerted antitumor functional effects by a decrease in proliferation and an increase in apoptosis in CRC cells.	AZD 1480	25-32	signal transducer and activator of transcription 3	Homo sapiens	93-99
24577942-0	2014	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.	AZD 1480	56-63	Janus kinase 1	Mus musculus	29-35
25149535-1	2014	AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth.	AZD 1480	0-7	Janus kinase 1	Mus musculus	61-67
25149535-1	2014	AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth.	AZD 1480	0-7	signal transducer and activator of transcription 3	Mus musculus	90-95
25149535-5	2014	However, AZD1480 enhanced the suppressive capacity of murine MDSCs while at the same time impairing the proliferative as well as the IFN-gamma secretion capacity of murine T cells.	AZD 1480	9-16	interferon gamma	Mus musculus	133-142
25149535-6	2014	The addition of AZD1480 to co-cultures of human MDSCs and T cells does not affect the suppressive activity of MDSCs but it does reduce the IFN-gamma secretion and the proliferative capacity of T cells.	AZD 1480	16-23	interferon gamma	Homo sapiens	139-148
24577942-0	2014	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.	AZD 1480	56-63	Janus kinase 1	Mus musculus	29-33
24577942-0	2014	Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.	AZD 1480	56-63	interleukin 6	Mus musculus	82-86
24577942-8	2014	Most importantly, pharmacologic inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced signaling, migratory prostate cancer cell phenotypes, and metastatic dissemination of prostate cancer in vivo in nude mice.	AZD 1480	56-63	Janus kinase 1	Mus musculus	46-50
24577942-8	2014	Most importantly, pharmacologic inhibition of Jak1/2 by AZD1480 suppressed IL-6-induced signaling, migratory prostate cancer cell phenotypes, and metastatic dissemination of prostate cancer in vivo in nude mice.	AZD 1480	56-63	interleukin 6	Mus musculus	75-79
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	48-52
24577942-9	2014	In conclusion, we demonstrate that the cytokine IL-6 directly promotes prostate cancer metastasis in vitro and in vivo via Jak-Stat3 signaling pathway, and that IL-6-driven metastasis can be effectively suppressed by pharmacologic targeting of Jak1/2 using Jak1/2 inhibitor AZD1480.	AZD 1480	274-281	interleukin 6	Mus musculus	161-165
24398427-4	2014	Here, we investigated whether the small-molecule Jak1/2 inhibitor AZD1480 confers therapeutic benefits in two mouse models of inflammation-associated gastrointestinal cancer, which are strictly dependent of excessive Stat3 activation.	AZD 1480	66-73	Janus kinase 1	Mus musculus	49-55
24398427-6	2014	We find that systemic administration of AZD1480 readily replicates this effect, which is associated with reduced Stat3 activation and correlates with diminished tumor cell proliferation and increased apoptosis.	AZD 1480	40-47	signal transducer and activator of transcription 3	Mus musculus	113-118
24323580-6	2014	We have used AZD1480, a JAK1/2 inhibitor, to investigate the therapeutic potential of inhibiting the JAK/STAT pathway in models of EAE.	AZD 1480	13-20	Janus kinase 1	Mus musculus	24-30
24359159-2	2014	Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor.	AZD 1480	60-67	Janus kinase 2	Mus musculus	169-173
24323580-7	2014	AZD1480 treatment inhibits disease severity in myelin oligodendrocyte glycoprotein-induced classical and atypical EAE models by preventing entry of immune cells into the brain, suppressing differentiation of Th1 and Th17 cells, deactivating myeloid cells, inhibiting STAT activation in the brain, and reducing expression of proinflammatory cytokines and chemokines.	AZD 1480	0-7	myelin oligodendrocyte glycoprotein	Mus musculus	47-82
24323580-7	2014	AZD1480 treatment inhibits disease severity in myelin oligodendrocyte glycoprotein-induced classical and atypical EAE models by preventing entry of immune cells into the brain, suppressing differentiation of Th1 and Th17 cells, deactivating myeloid cells, inhibiting STAT activation in the brain, and reducing expression of proinflammatory cytokines and chemokines.	AZD 1480	0-7	negative elongation factor complex member C/D, Th1l	Mus musculus	208-211
24323580-9	2014	AZD1480 treatment was also effective in reducing ongoing paralysis induced by adoptive transfer of either pathogenic Th1 or Th17 cells.	AZD 1480	0-7	negative elongation factor complex member C/D, Th1l	Mus musculus	117-120
23531921-0	2013	Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.	AZD 1480	54-61	signal transducer and activator of transcription 3	Mus musculus	14-19
24238495-3	2014	We investigated the effect of the JAK1/2 inhibitor AZD1480 on lung tumors induced by an activating EGFR mutation.	AZD 1480	51-58	epidermal growth factor receptor	Mus musculus	99-103
24238495-17	2014	CONCLUSION: AZD1480 may be effective against lung tumors driven by an activating EGFR mutation.	AZD 1480	12-19	epidermal growth factor receptor	Mus musculus	81-85
24158701-3	2013	EXPERIMENTAL DESIGN: JAK1 and JAK2 were inhibited by AZD1480 or siRNAs, and the effect of inhibition of JAK gene family on SCLC cell viability was evaluated.	AZD 1480	53-60	Janus kinase 1	Homo sapiens	21-25
24158701-3	2013	EXPERIMENTAL DESIGN: JAK1 and JAK2 were inhibited by AZD1480 or siRNAs, and the effect of inhibition of JAK gene family on SCLC cell viability was evaluated.	AZD 1480	53-60	Janus kinase 2	Homo sapiens	30-34
24158701-9	2013	Moreover, SCLCs underwent apoptosis after AZD1480 treatment as exemplified by the downregulation of MCL1, the accumulation of cleaved caspase 3, cleaved PARP, and increase of annexin-V-positive cells.	AZD 1480	42-49	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	100-104
24158701-9	2013	Moreover, SCLCs underwent apoptosis after AZD1480 treatment as exemplified by the downregulation of MCL1, the accumulation of cleaved caspase 3, cleaved PARP, and increase of annexin-V-positive cells.	AZD 1480	42-49	collagen type XI alpha 2 chain	Homo sapiens	153-157
24158701-9	2013	Moreover, SCLCs underwent apoptosis after AZD1480 treatment as exemplified by the downregulation of MCL1, the accumulation of cleaved caspase 3, cleaved PARP, and increase of annexin-V-positive cells.	AZD 1480	42-49	annexin A5	Homo sapiens	175-184
23531921-7	2013	AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc.	AZD 1480	0-7	cell division cycle 25A	Mus musculus	176-182
23531921-7	2013	AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc.	AZD 1480	0-7	B cell leukemia/lymphoma 2	Mus musculus	205-210
23942095-0	2013	Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.	AZD 1480	67-74	Janus kinase 2	Mus musculus	28-32
23942095-0	2013	Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.	AZD 1480	67-74	signal transducer and activator of transcription 5A	Mus musculus	33-38
23942095-0	2013	Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.	AZD 1480	67-74	Janus kinase 2	Mus musculus	52-56
23942095-3	2013	Here, we show that pharmacologic targeting of Jak2-dependent Stat5a/b signaling by the Jak2 inhibitor AZD1480 blocks castrate-resistant growth of prostate cancer.	AZD 1480	102-109	Janus kinase 2	Mus musculus	46-50
23942095-3	2013	Here, we show that pharmacologic targeting of Jak2-dependent Stat5a/b signaling by the Jak2 inhibitor AZD1480 blocks castrate-resistant growth of prostate cancer.	AZD 1480	102-109	signal transducer and activator of transcription 5A	Mus musculus	61-67
23942095-3	2013	Here, we show that pharmacologic targeting of Jak2-dependent Stat5a/b signaling by the Jak2 inhibitor AZD1480 blocks castrate-resistant growth of prostate cancer.	AZD 1480	102-109	Janus kinase 2	Mus musculus	87-91
23942095-4	2013	EXPERIMENTAL DESIGN: Efficacy of AZD1480 in disrupting Jak2-Stat5a/b signaling and decreasing prostate cancer cell viability was evaluated in prostate cancer cells.	AZD 1480	33-40	Janus kinase 2	Mus musculus	55-59
23942095-4	2013	EXPERIMENTAL DESIGN: Efficacy of AZD1480 in disrupting Jak2-Stat5a/b signaling and decreasing prostate cancer cell viability was evaluated in prostate cancer cells.	AZD 1480	33-40	signal transducer and activator of transcription 5A	Mus musculus	60-66
23942095-7	2013	RESULTS: AZD1480 robustly inhibited Stat5a/b phosphorylation, dimerization, nuclear translocation, DNA binding, and transcriptional activity in prostate cancer cells.	AZD 1480	9-16	signal transducer and activator of transcription 5A	Mus musculus	36-42
23942095-8	2013	AZD1480 reduced prostate cancer cell viability sustained by Jak2-Stat5a/b signaling through induction of apoptosis, which was rescued by constitutively active Stat5a/b.	AZD 1480	0-7	Janus kinase 2	Mus musculus	60-64
23942095-8	2013	AZD1480 reduced prostate cancer cell viability sustained by Jak2-Stat5a/b signaling through induction of apoptosis, which was rescued by constitutively active Stat5a/b.	AZD 1480	0-7	signal transducer and activator of transcription 5A	Mus musculus	65-71
23942095-8	2013	AZD1480 reduced prostate cancer cell viability sustained by Jak2-Stat5a/b signaling through induction of apoptosis, which was rescued by constitutively active Stat5a/b.	AZD 1480	0-7	signal transducer and activator of transcription 5A	Mus musculus	159-165
23942095-9	2013	In mice, pharmacologic targeting of Stat5a/b by AZD1480 potently blocked growth of primary androgen-dependent as well as recurrent castrate-resistant CWR22Pc xenograft tumors, and prolonged survival of tumor-bearing mice versus vehicle or docetaxel-treated mice.	AZD 1480	48-55	signal transducer and activator of transcription 5A	Mus musculus	36-42
23942095-10	2013	Finally, nine of 12 clinical prostate cancers responded to AZD1480 by extensive apoptotic epithelial cell loss, concurrent with reduced levels of nuclear Stat5a/b.	AZD 1480	59-66	signal transducer and activator of transcription 5A	Mus musculus	154-160
23531921-7	2013	AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc.	AZD 1480	0-7	baculoviral IAP repeat-containing 5	Mus musculus	215-223
23531921-7	2013	AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc.	AZD 1480	0-7	tissue inhibitor of metalloproteinase 1	Mus musculus	255-261
23531921-9	2013	Tumors from AZD1480-treated mice showed inhibition of activated STAT3 as well as decreased expression of STAT3 downstream targets.	AZD 1480	12-19	signal transducer and activator of transcription 3	Mus musculus	64-69
23531921-9	2013	Tumors from AZD1480-treated mice showed inhibition of activated STAT3 as well as decreased expression of STAT3 downstream targets.	AZD 1480	12-19	signal transducer and activator of transcription 3	Mus musculus	105-110
23531921-10	2013	Our study provides strong evidence of the anti-tumor growth potency of JAK inhibitor AZD1480 in pediatric solid tumors, providing proof-of principle that inhibition of the JAK/STAT3 signal transduction could be a promising therapeutic target for high-risk pediatric solid tumors.	AZD 1480	85-92	signal transducer and activator of transcription 3	Mus musculus	176-181
23531921-2	2013	AZD1480, a pharmacological JAK1/2 inhibitor, exhibits anti-tumor potency in multiple adult malignancies.	AZD 1480	0-7	Janus kinase 1	Mus musculus	27-33
23531921-5	2013	Our data indicate that AZD1480 blocks endogenous as well as IL-6 induced STAT3 activation.	AZD 1480	23-30	interleukin 6	Mus musculus	60-64
23531921-5	2013	Our data indicate that AZD1480 blocks endogenous as well as IL-6 induced STAT3 activation.	AZD 1480	23-30	signal transducer and activator of transcription 3	Mus musculus	73-78
23531921-7	2013	AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc.	AZD 1480	0-7	signal transducer and activator of transcription 3	Mus musculus	108-113
23847256-0	2013	AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	36-40
24083752-4	2013	After treatment with AZD1480 plus cisplatin, the apoptosis rate increased significantly while the expression level of p-STAT3 protein was decreased.	AZD 1480	21-28	signal transducer and activator of transcription 3	Homo sapiens	120-125
24083752-5	2013	CONCLUSION: AZD1480 can inhibit the proliferation, invasion, metastasis and clone formation of SKOV3 cells, induce cellulsar apoptosis, increase the chemotherapeutic sensitivity and reduce the expression level of p-STAT3 protein.	AZD 1480	12-19	signal transducer and activator of transcription 3	Homo sapiens	215-220
23847256-1	2013	BACKGROUND: AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).	AZD 1480	12-19	Janus kinase 1	Homo sapiens	85-89
23847256-1	2013	BACKGROUND: AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2).	AZD 1480	12-19	Janus kinase 2	Homo sapiens	94-98
22355274-0	2012	Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.	AZD 1480	51-58	Janus kinase 1	Mus musculus	33-39
23013619-4	2012	Administration of the JAK/STAT3 inhibitor AZD1480 alone and in combination with cediranib reduced tumor hypoxia and the infiltration of VEGF inhibitor-induced p-STAT3 macrophages.	AZD 1480	42-49	signal transducer and activator of transcription 3	Homo sapiens	26-31
23013619-4	2012	Administration of the JAK/STAT3 inhibitor AZD1480 alone and in combination with cediranib reduced tumor hypoxia and the infiltration of VEGF inhibitor-induced p-STAT3 macrophages.	AZD 1480	42-49	vascular endothelial growth factor A	Homo sapiens	136-140
23013619-4	2012	Administration of the JAK/STAT3 inhibitor AZD1480 alone and in combination with cediranib reduced tumor hypoxia and the infiltration of VEGF inhibitor-induced p-STAT3 macrophages.	AZD 1480	42-49	signal transducer and activator of transcription 3	Homo sapiens	161-166
23013619-5	2012	Thus, the combination of AZD1480 with cediranib markedly reduced tumor volume, and microvascular density, indicating that up regulation of the STAT3 pathway can mediate resistance to antiangiogenic therapy and combinational approaches may delay or overcome resistance.	AZD 1480	25-32	signal transducer and activator of transcription 3	Homo sapiens	143-148
21926964-7	2012	Our results further indicated that these mutations also conferred cross-resistance to all JAK2 kinase inhibitors tested, including AZD1480, TG101348, lestaurtinib (CEP-701) and CYT-387.	AZD 1480	131-138	Janus kinase 2	Mus musculus	90-94
22355274-3	2012	AZD1480 is a novel small molecule inhibitor of Jak1/2, which is a key mediator of STAT3 activation.	AZD 1480	0-7	Janus kinase 1	Mus musculus	47-53
22355274-3	2012	AZD1480 is a novel small molecule inhibitor of Jak1/2, which is a key mediator of STAT3 activation.	AZD 1480	0-7	signal transducer and activator of transcription 3	Mus musculus	82-87
23056499-0	2012	AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.	AZD 1480	0-7	ret proto-oncogene	Homo sapiens	43-46
23056499-3	2012	Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET.	AZD 1480	53-60	Janus kinase 1	Homo sapiens	34-38
23056499-3	2012	Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET.	AZD 1480	53-60	ret proto-oncogene	Homo sapiens	147-150
23056499-7	2012	However, AZD1480 repressed the growth of STAT3- deficient TPC-1 cells in vitro and in vivo, demonstrating that its effects in this cell line were independent of STAT3 in the tumor cells.	AZD 1480	9-16	signal transducer and activator of transcription 3	Homo sapiens	41-46
23056499-7	2012	However, AZD1480 repressed the growth of STAT3- deficient TPC-1 cells in vitro and in vivo, demonstrating that its effects in this cell line were independent of STAT3 in the tumor cells.	AZD 1480	9-16	two pore segment channel 1	Homo sapiens	58-63
23056499-9	2012	In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells).	AZD 1480	15-22	ret proto-oncogene	Homo sapiens	86-89
23056499-9	2012	In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells).	AZD 1480	15-22	ret proto-oncogene	Homo sapiens	140-143
23056499-9	2012	In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. via JAK/phospho-STAT3 inhibition in endothelial cells).	AZD 1480	15-22	signal transducer and activator of transcription 3	Homo sapiens	242-247
23056499-10	2012	Thus, AZD1480 should be considered as a therapeutic agent for the treatment of RET- activated thyroid cancers.	AZD 1480	6-13	ret proto-oncogene	Homo sapiens	79-82
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	203-207
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	mitogen-activated protein kinase 1	Homo sapiens	212-258
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	mitogen-activated protein kinase 3	Homo sapiens	260-266
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	C-X-C motif chemokine ligand 10	Homo sapiens	283-288
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	C-C motif chemokine ligand 5	Homo sapiens	290-296
22829094-3	2011	AZD1480 at low doses (0.1-1 mu) potently inhibited STATs phosphorylation, but did not predictably result in antiproliferative effects, as it activated a negative-feedback loop causing phosphorylation of JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2), and increased IP-10, RANTES and interleukin (IL)-8 concentrations in the supernatants.	AZD 1480	0-7	C-X-C motif chemokine ligand 8	Homo sapiens	301-319
22829094-4	2011	Inhibition of the ERK activity by mitogen-activated extracellular signal regulated kinase (MEK) inhibitors (UO126 and PD98059) enhanced the cytotoxic activity of AZD1480.	AZD 1480	162-169	mitogen-activated protein kinase 3	Homo sapiens	18-21
22829094-4	2011	Inhibition of the ERK activity by mitogen-activated extracellular signal regulated kinase (MEK) inhibitors (UO126 and PD98059) enhanced the cytotoxic activity of AZD1480.	AZD 1480	162-169	mitogen-activated protein kinase kinase 7	Homo sapiens	91-94
22829094-5	2011	Interestingly, submicromolar concentrations of AZD1480 demonstrated significant immunoregulatory effects by downregulating T-helper 2 cytokines and chemokines, including IL-13 and thymus- and activation-regulated chemokine, and the surface expression of the immunosuppressive programmed death ligands 1 and 2.	AZD 1480	47-54	interleukin 13	Homo sapiens	170-222
22027691-4	2011	AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis.	AZD 1480	0-7	Janus kinase 1	Homo sapiens	71-75
22027691-4	2011	AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	77-81
22027691-4	2011	AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis.	AZD 1480	0-7	signal transducer and activator of transcription 3	Homo sapiens	87-93
22027691-7	2011	AZD1480 inhibits constitutive and stimulus-induced phosphorylation of JAK2 and STAT-3 in these GBM xenograft tumors in vitro, downstream gene expression, and inhibits cell proliferation.	AZD 1480	0-7	Janus kinase 2	Homo sapiens	70-74
22027691-7	2011	AZD1480 inhibits constitutive and stimulus-induced phosphorylation of JAK2 and STAT-3 in these GBM xenograft tumors in vitro, downstream gene expression, and inhibits cell proliferation.	AZD 1480	0-7	signal transducer and activator of transcription 3	Homo sapiens	79-85
22027691-8	2011	Furthermore, AZD1480 suppresses STAT-3 activation in the glioma-initiating cell population in GBM tumors.	AZD 1480	13-20	signal transducer and activator of transcription 3	Homo sapiens	32-38
22027691-9	2011	In vivo, AZD1480 inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial GBM tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by AZD1480 should be considered for study in the treatment of patients with GBM tumors.	AZD 1480	9-16	signal transducer and activator of transcription 3	Mus musculus	137-143
22027691-9	2011	In vivo, AZD1480 inhibits the growth of subcutaneous tumors and increases survival of mice bearing intracranial GBM tumors by inhibiting STAT-3 activity, indicating that pharmacologic inhibition of the JAK/STAT-3 pathway by AZD1480 should be considered for study in the treatment of patients with GBM tumors.	AZD 1480	9-16	signal transducer and activator of transcription 3	Mus musculus	206-212
21164517-0	2011	The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.	AZD 1480	24-31	signal transducer and activator of transcription 3	Homo sapiens	39-44
21164517-0	2011	The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.	AZD 1480	24-31	fibroblast growth factor receptor 3	Homo sapiens	49-54
21164517-2	2011	We investigated the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK signal transduction and its biological consequences on the human myeloma-derived cell lines U266 and Kms.11.	AZD 1480	69-76	interleukin 6	Homo sapiens	81-85
21164517-4	2011	These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.	AZD 1480	30-37	Janus kinase 2	Homo sapiens	103-107
21164517-4	2011	These biological responses to AZD1480 are associated with concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.	AZD 1480	30-37	signal transducer and activator of transcription 3	Homo sapiens	109-114
21164517-6	2011	Examination of a wider variety of myeloma cells (RPMI 8226, OPM-2, NCI-H929, Kms.18, MM1.S and IM-9), as well as primary myeloma cells, showed that AZD1480 has broad efficacy.	AZD 1480	148-155	plexin B2	Homo sapiens	85-88
21164517-8	2011	Importantly, AZD1480 induces cell death of Kms.11 cells grown in the presence of HS-5 bone marrow (BM)-derived stromal cells and inhibits tumor growth in a Kms.11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels.	AZD 1480	13-20	fibroblast growth factor receptor 3	Mus musculus	225-230
21164517-8	2011	Importantly, AZD1480 induces cell death of Kms.11 cells grown in the presence of HS-5 bone marrow (BM)-derived stromal cells and inhibits tumor growth in a Kms.11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels.	AZD 1480	13-20	Janus kinase 2	Mus musculus	240-244
21164517-8	2011	Importantly, AZD1480 induces cell death of Kms.11 cells grown in the presence of HS-5 bone marrow (BM)-derived stromal cells and inhibits tumor growth in a Kms.11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels.	AZD 1480	13-20	signal transducer and activator of transcription 3	Mus musculus	254-259
21164517-8	2011	Importantly, AZD1480 induces cell death of Kms.11 cells grown in the presence of HS-5 bone marrow (BM)-derived stromal cells and inhibits tumor growth in a Kms.11 xenograft mouse model, accompanied with inhibition of phospho-FGFR3, phospho-JAK2, phospho-STAT3 and Cyclin D2 levels.	AZD 1480	13-20	cyclin D2	Mus musculus	264-273
21164517-9	2011	In sum, AZD1480 blocks proliferation, survival, FGFR3 and JAK/STAT3 signaling in myeloma cells cultured alone or cocultured with BM stromal cells, and in vivo.	AZD 1480	8-15	fibroblast growth factor receptor 3	Homo sapiens	48-53
21164517-9	2011	In sum, AZD1480 blocks proliferation, survival, FGFR3 and JAK/STAT3 signaling in myeloma cells cultured alone or cocultured with BM stromal cells, and in vivo.	AZD 1480	8-15	signal transducer and activator of transcription 3	Homo sapiens	62-67
21138246-3	2011	Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.	AZD 1480	111-118	Janus kinase 2	Homo sapiens	132-136
19962667-0	2009	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.	AZD 1480	19-26	Janus kinase 2	Homo sapiens	4-8
19962667-0	2009	The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.	AZD 1480	19-26	signal transducer and activator of transcription 3	Homo sapiens	43-48
19962667-5	2009	The Jak2 inhibitor AZD1480 suppresses the growth of human solid tumor xenografts harboring persistent Stat3 activity.	AZD 1480	19-26	Janus kinase 2	Homo sapiens	4-8
19962667-5	2009	The Jak2 inhibitor AZD1480 suppresses the growth of human solid tumor xenografts harboring persistent Stat3 activity.	AZD 1480	19-26	signal transducer and activator of transcription 3	Homo sapiens	102-107
21920898-4	2011	In this study, we show that AZD1480 inhibits STAT3 in tumor-associated myeloid cells, reducing their number and inhibiting tumor metastasis.	AZD 1480	28-35	signal transducer and activator of transcription 3	Homo sapiens	45-50
21920898-9	2011	Together, our results indicated that AZD1480 can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells.	AZD 1480	37-44	signal transducer and activator of transcription 3	Homo sapiens	115-120
21751940-4	2011	We also review the rationale to use novel STAT3 inhibitors and list some of these inhibitors such as STA-21, IS3 295, S3I- M2001 and small molecule JAK2 inhibitors AZD1480 and AZ960 that have been found to be efficient against tumors.	AZD 1480	164-171	signal transducer and activator of transcription 3	Homo sapiens	42-47
21751940-4	2011	We also review the rationale to use novel STAT3 inhibitors and list some of these inhibitors such as STA-21, IS3 295, S3I- M2001 and small molecule JAK2 inhibitors AZD1480 and AZ960 that have been found to be efficient against tumors.	AZD 1480	164-171	Janus kinase 2	Homo sapiens	148-152